05/16/22 8:00 AMAMEX : SYN earningsSynthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- -RHEA-AIneutral
05/10/22 8:00 AMAMEX : SYN clinical trialSynthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical TrialSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas ofRHEA-AIneutral
05/09/22 8:00 AMAMEX : SYN conferencesearningsSynthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial ResultsSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, atRHEA-AIneutral
05/05/22 8:00 AMAMEX : SYN managementSynthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology PipelineSynthetic Biologics, Inc. (NYSE American: SYN), a diversifiedRHEA-AIneutral
05/04/22 8:00 AMAMEX : SYN Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)- VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential to improve systemic delivery and extend therapeutic efficacy through a multi-dosing strategy- - Data to be featured in an oral presentation on Monday, May 16 at 5:15 p.m. ET- ROCKVILLE, Md., May 04,RHEA-AIneutral
03/28/22 4:05 PMAMEX : SYN clinical trialSynthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors-Data support VCN-01 acceptable safety profile with encouraging biological and clinical activity, and identify recommended Phase 2 dose (RP2D)- -Publication further supports the development of Synthetic Biologics’ novel oncolytic adenovirus (OV) platform- ROCKVILLE, Md., March 28, 2022 (GLOBERHEA-AIneutral
03/23/22 8:00 AMAMEX : SYN managementSynthetic Biologics Announces Management Transitions in Support of Strategic Transformation-Frank Tufaro, Ph.D., appointed as Chief Operating Officer of Synthetic Biologics, transitioning from Chief Operating Officer of VCN Biosciences- -Manel Cascallό, Ph.D., appointed as General Director of Synthetic Biologics’ European Subsidiary, transitioning from Chief Operating Officer of VCNRHEA-AIvery positive
03/22/22 4:05 PMAMEX : SYN conferencesSynthetic Biologics to Participate in the Maxim 2022 Virtual Growth ConferenceSynthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update andRHEA-AIneutral
03/16/22 4:05 PMAMEX : SYN earningsSynthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023-RHEA-AIpositive
03/11/22 8:00 AMAMEX : SYN acquisitionSynthetic Biologics Completes Acquisition of VCN Biosciences- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - - Strong cash position to support multiple inflection points for VCN-01 with the start of a Phase 2 trial in combination with standard-of-care chemotherapy in patients withRHEA-AIvery positive